Apart from trade and services, the economic slowdown in China is already having an impact on German companies.
“The expectations of German companies are lower than they have been for years,” said the German Chamber of Foreign Trade (AHK) in Beijing at the publication of its annual member survey on the business climate. Only a quarter (27%) of German companies expect to achieve their business targets in the People’s Republic this year.
A prime reason for this decline is the slowdown in the Chinese economic growth; in the third quarter of 2019, the growth rate of 6% was lower than it has been for almost three decades. Experts cited the US trade war with China, investor unease with the prevailing geopolitical climate, and China’s efforts to combat growing debt as causes. Most recently, Beijing and Washington have signaled their intention to conclude an agreement to ease the conflict.
Medical cannabis as the next business frontier in China, Europe, and the U.S.
The Chinese economy might be causing jitters in the global economy but there are other opportunities for investors opening up. Relaxing attitudes towards medical cannabis has created numerous new investment opportunities in the European and Asian markets.
Investors will need access to cannabis investment tools like Hemp.IM to make the most of what could be one of the next big opportunities in the world markets.
German automotive and mechanical engineering companies particularly affected
In the automotive and mechanical engineering sectors in particular, forecasts also fell significantly among German companies in view of this mixed situation. According to the Chamber, sentiment was suffering from the slowdown in China’s economy coupled with the effects of the trade conflict. Thus, 83 percent of German companies feel directly or indirectly affected by the trade war between China and the USA.
For the coming year, too, only tentative signs of a recovery can be discerned. Jens Hildebrandt, managing board member of the AHK in Beijing, said: “2020 will very probably be marked by the uncertainties caused by the trade conflict and the slowdown in global and Chinese economic growth.”
China is still an important market that offers valuable business opportunities for the companies surveyed. However, the growth potential of German companies in China is still limited by market access restrictions and complex regulatory frameworks. According to the Chamber, indirect restrictions such as the granting of licenses, disproportionate tendering procedures, a lack of participation in the development of industry standards and insufficient lead times for the implementation of new regulations represent the greatest hurdles for German companies.
For every second respondent, legal uncertainty and the diffused legal framework as well as technology transfer were the most significant challenges in China’s business. The Chamber called for the conclusion of a comprehensive investment agreement between the EU and China. Hildebrand said that an agreement that includes fair market access would provide new impetus.
First published in SPIEGELONLINE, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.
Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.
DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.
This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.
Another biotech gem from Switzerland secures growth capital
A biotech spin-off from the Universities of Zurich and Basel has received new funds from a financing round with renowned...
Industrial espionage costs German companies $229.4 billion
According to the Federation of German Industries (BDI), data theft, industrial espionage and sabotage have cost German companies $229.1 billion...
French Real Estate Crowdfunding grew by 80% in 2019
Real estate crowdfunding is a new way for investors to raise money for their affairs. Crowdfunding for real estate brings...
Growing Capacity: Why Smart Expansion Is Key To Success Among Cannabis Growers
Soaring demand is driving the cannabis market to new highs, as thousands of under served clients can finally obtain their...
Investors react to the Sanofi-Regeneron collaboration
Regeneron Pharmaceuticals Inc shares rebounded as investors found out about collaboration partner Sanofi SA’s liquidation of its Regeneron stake. The...
- Crypto6 days ago
Swiss licensed crypto bank is expanding into 9 new markets
- Biotech7 days ago
Geman Biotech Stocks: Mologen (MGNK) goes insolvent while MorphoSys (MOR) strengthens its position
- Business4 days ago
Where Social Media is Headed in 2020
- Cannabis7 days ago
Brazilian health authority approves registration of cannabis medicines